Phaseline

Companies › Jiangsu Aidea Pharmaceutical Group

Jiangsu Aidea Pharmaceutical Group: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Other, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADB116 for Injection–Phase 1Healthy Adult ParticipantsDec 2026
ACC017
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
–Phase 1Infection, Human Immunodeficiency VirusJun 2027
ACC085 Injection–Phase 1Healthy Adult ParticipantsJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07729839ADB116 for InjectionPhase 1Healthy Adult ParticipantsOtherDec 2026
NCT07711210ACC017Phase 1Infection, Human Immunodeficiency VirusInfectious diseaseJun 2027
NCT07835633ACC085 InjectionPhase 1Healthy Adult ParticipantsOtherJul 2028
NCT07711223ACC017Phase 1Infection, Human Immunodeficiency VirusInfectious diseaseAug 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.